NDAORALFOR SOLUTION
Approved
Dec 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HELICOSOL (Urea C-13) is an oral diagnostic agent administered as a solution for reconstitution. It is a stable isotope diagnostic used to detect Helicobacter pylori infection in the stomach through breath testing methodology.
LOE Approaching
Product is nearing loss of exclusivity with limited current job openings, suggesting a mature or contracting commercial footprint.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HELICOSOL currently shows zero linked job openings, reflecting a mature diagnostic product with limited hiring activity. Career opportunities on this brand are minimal and likely reserved for specialized roles in diagnostic sales or support functions.
Diagnostic Sales RepresentativeProduct Manager
Worked on HELICOSOL at GT Metabolic Solutions? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.